Can Rheumatoid Arthritis Be Cured? RA Remission Explained

What does 'remission' actually mean in RA?

Remission in RA means the disease is under very tight control — inflammation markers are low, joint tenderness and swelling are minimal, and daily function is largely preserved. It is not the same as a cure. The immune system changes that drive RA remain present, and in most cases medication needs to continue to keep the disease quiet.

Rheumatologists use standardized measures — such as the Disease Activity Score (DAS28), the Clinical Disease Activity Index (CDAI), or the American College of Rheumatology/EULAR Boolean remission criteria — to define and track remission. Reaching remission, or at least low disease activity, is the explicit target of modern RA care 1Ref 1Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, et al. (2021).2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Treat-to-target strategy, DMARD escalation, and remission as the primary goal of RA management.

How is RA treated, and what are the chances of reaching remission?

Treatment strategy follows a "treat-to-target" approach: start a disease-modifying antirheumatic drug (DMARD) early, measure disease activity regularly, and escalate if the target is not reached within a few months.

Conventional DMARDs — methotrexate is the most widely used first-line agent. Many people respond well to methotrexate alone or in combination with other conventional DMARDs.

Biologic DMARDs — when conventional therapy is insufficient, biologics targeting specific pathways (such as TNF inhibitors, IL-6 receptor blockers, or drugs that affect T-cell or B-cell activity) are added or substituted 1Ref 1Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, et al. (2021).2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Treat-to-target strategy, DMARD escalation, and remission as the primary goal of RA management. The 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis details these choices. The 2022 EULAR recommendations further confirm the treat-to-target approach with remission as the primary goal 3Ref 3Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. (2023).EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.Treat-to-target strategy with remission as the primary goal; DMARD sequencing and escalation; tapering during sustained remission.

Targeted synthetic DMARDs (JAK inhibitors) — another class of oral agents available for moderate-to-severe disease.

Remission rates vary by disease duration, how early treatment started, and individual biology. People treated early and aggressively are more likely to reach sustained remission than those whose disease was undertreated for years.

What happens if you stop medication while in remission?

Attempting to taper or stop medication during sustained remission is sometimes considered — called "tapering" — but it carries real risk. Studies show that a significant proportion of people who stop their DMARD while in clinical remission experience a disease flare within months to a year.

Tapering should only happen slowly and under close rheumatology supervision, with frequent monitoring. Some people do successfully maintain remission off medication, particularly those who achieved remission quickly and have had stable disease for a long time, but this is not predictable in advance. Stopping abruptly without medical guidance risks joint damage that may not fully reverse.

Does RA get worse over time without treatment?

Untreated or undertreated RA tends to progress. Chronic inflammation erodes cartilage and bone in affected joints, leading to lasting structural damage and functional loss. The joint damage seen on imaging (erosions) is largely irreversible once it occurs — making early, effective treatment the most important factor in long-term joint preservation 2Ref 2McInnes IB, Schett G (2011).The pathogenesis of rheumatoid arthritis.Persistent inflammation leads to joint erosion and structural damage in untreated RA.

Beyond joints, uncontrolled RA is associated with higher cardiovascular risk, greater rates of certain infections, and reduced life expectancy compared to the general population 4Ref 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (2022).Rheumatoid Arthritis: Symptoms, Causes, and Risk Factors.Systemic complications of uncontrolled RA including cardiovascular risk and effects on lungs and heart. Controlling inflammation reduces these systemic risks as well.

What factors affect the likelihood of remission?

Several factors are associated with better outcomes:

• Early diagnosis and treatment. Starting a DMARD within weeks of symptom onset leads to substantially better long-term joint outcomes than waiting months or years.
• Seronegative disease. People who test negative for rheumatoid factor and anti-CCP antibodies sometimes have milder disease, though this is not universal.
• Non-smoking. Smoking reduces the effectiveness of some biologic treatments, particularly TNF inhibitors, and is associated with more severe disease.
• Adherence to treatment. Consistent use of prescribed DMARDs, even when feeling well, maintains the suppression of disease activity.

Lifestyle factors — regular physical activity appropriate to current joint status, a balanced diet, and stress management — support overall function and wellbeing, though they do not replace medication.

Who manages RA, and when should I see a rheumatologist?

RA is managed by a rheumatologist — a specialist in inflammatory joint and autoimmune diseases. Primary care providers can raise the concern and order initial bloodwork, but diagnosis, DMARD initiation, and ongoing monitoring require rheumatology expertise.

If you have not yet been evaluated and have persistent joint pain and swelling — especially if it is worse in the morning and involves multiple joints — a rheumatology referral is appropriate. Gale can help you prepare for that visit and understand what to expect from the evaluation process.